The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
The status of platinum anticancer drugs in the clinic and in clinical trials
Open accessAbstract
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations. During this time there have been more failures than successes with the development of 14 drugs being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial (satraplatin, picoplatin, Lipoplatin and ProLindac). No new small molecule platinum drug has entered clinical trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade. In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials, and discuss the results in the context of where we believe the field will develop over the next decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Welt, F. G. P., & Edelman, E. R. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)90003-x · Cited by 863
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Cisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 729
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Methods for Genotyping Single Nucleotide Polymorphisms
Kwok, P.-Y. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.235 · Cited by 580
Medical aspects of sulphur mustard poisoning
Kehe, K., & Szinicz, L. (2005) · Toxicology · doi:10.1016/j.tox.2005.06.014 · Cited by 439
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Ultrasound triggered release of cisplatin from liposomes in murine tumors
Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., & Barenholz, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.007 · Cited by 305
Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., & Amantea, M. A. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050855 · Cited by 275
Exploring the cellular accumulation of metal complexes
Puckett, C. A., Ernst, R. J., & Barton, J. K. (2010) · Dalton Trans. · doi:10.1039/b922209j · Cited by 255
New platinum complexes with anti-tumour activity
Connors, T. A., Jones, M., Ross, W. C. J., Braddock, P. D., Khokhar, A. R., & Tobe, M. L. (1972) · Chemico-Biological Interactions · doi:10.1016/0009-2797(72)90078-6 · Cited by 240
Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.
Schroeder, A., Avnir, Y., Weisman, S., Najajreh, Y., Gabizon, A., Talmon, Y., Kost, J., & Barenholz, Y. (2007) · Langmuir · doi:10.1021/la0631668 · Cited by 239
Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer, C., Mulder, N. H., Timmer‐Bosscha, H., Sluiter, W. J., Meersma, G. J., & de Vries, E. G. E. (1992) · PubMed · Cited by 216
Holford, J., Sharp, S., Murrer, B., Abrams, M., & Kelland, L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.59 · Cited by 196
Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., & Stewart, J. S. W. (2001) · Annals of Oncology · doi:10.1023/a:1011199028318 · Cited by 182
Friedman, H. S., Krischer, J. P., Burger, P. C., et al. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.249 · Cited by 181
A Third Mode of DNA Binding: Phosphate Clamps by a Polynuclear Platinum Complex
Komeda, S., Moulaei, T., Woods, K. K., Chikuma, M., Farrell, N. P., & Williams, L. D. (2006) · Journal of the American Chemical Society · doi:10.1021/ja062851y · Cited by 178
Lordick, F., Luber, B., Lorenzen, S., Hegewisch-Becker, S., Folprecht, G., Wöll, E., Decker, T., Endlicher, E., Röthling, N., Schuster, T., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605521 · Cited by 176
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
Nowotnik, D. P., & Cvitkovic, E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.004 · Cited by 167
White, S. C., Lorigan, P. C., Margison, G. P., Margison, J. M., Martin, F., Thatcher, N., Anderson, H., & Ranson, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603345 · Cited by 152
DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464
Kašpárková, J., Zehnulová, J., Farrell, N. P., & Brabec, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208016200 · Cited by 147
Dragovich, T., Mendelson, D. S., Kurtin, S. E., Richardson, K., Hoff, D. D. V., & Hoos, A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0235-4 · Cited by 142
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
Piccart, M. J., Lamb, H., & Vermorken, J. B. (2001) · Annals of Oncology · doi:10.1023/a:1012259625746 · Cited by 139
Bandak, S., Goren, D., Horowitz, A. T., Tzemach, D., & Gabizon, A. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199911000-00007 · Cited by 137
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Kim, E. S., Lu, C., Khuri, F. R., Tonda, M. E., Glisson, B. S., Liu, D., Jung, M., Hong, W. K., & Herbst, R. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00278-1 · Cited by 136
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
Boulikas, T. (2004) · Oncology Reports · doi:10.3892/or.12.1.3 · Cited by 134
Jodrell, D. I., Evans, T. R. J., Steward, W. P., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N. A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.032 · Cited by 130
Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study
Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Deliconstantinos, G., Rigatos, S., Darli, E., Viliotou, V., & Stathopoulos, J. (2005) · Oncology Reports · doi:10.3892/or.13.4.589 · Cited by 128
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin
Terwogt, J. M. M., Groenewegen, G., Pluim, D., Maliepaard, M., Tibben, M. M., Huisman, A., Huinink, W. W. T. B., Schot, M. E., Welbank, H., Voest, E. E., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100371 · Cited by 124
Raynaud, F. I., Boxall, F. E., Goddard, P. M., Valenti, M. R., Jones, M. A., Murrer, B. A., Abrams, M., & Kèlland, L. R. (1997) · PubMed · Cited by 121
Pratesi, G., Perego, P., Polizzi, D., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690620 · Cited by 118
Rice, J. R., Gerberich, J. L., Nowotnik, D. P., & Howell, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2169 · Cited by 117
Campone, M., Rademaker-Lakhai, J. M., Bennouna, J., Howell, S. B., Nowotnik, D. P., Beijnen, J. H., & Schellens, J. H. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0397-0 · Cited by 115
Alberto, M. E., Lucas, M. F., Pavelka, M., & Russo, N. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9056835 · Cited by 107
Penson, R. T., Dizon, D. S., Cannistra, S. A., Roche, M. R., Krasner, C. N., Berlin, S. T., Horowitz, N. S., DiSilvestro, P., Matulonis, U. A., Lee, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7900 · Cited by 105
Mylonakis, N., Athanasiou, A. E., Ziras, N., Angel, J., Rapti, A., Lampaki, S., Politis, N., Karanikas, C. A., & Kosmas, C. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.017 · Cited by 98
Sood, P., Thurmond, K. B., Jacob, J. E., Waller, L. K., Silva, G. O., Stewart, D. R., & Nowotnik, D. P. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600517 · Cited by 92
Vail, D. M., Kurzman, I. D., Glawe, P., O’Brien, M. G., Chun, R., Garrett, L. D., Obradovich, J. E., Fred, R. M., Khanna, C., Colbern, G. T., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0469-8 · Cited by 91
Anderson, H. D., Wagstaff, J. D., Crowther, D., Swindell, R., Lind, M., McGregor, J., Timms, M. S., Brown, D., & Palmer, P. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90338-0 · Cited by 91
Laurie, S. A., Siu, L. L., Winquist, E., Maksymiuk, A. W., Harnett, E. L., Walsh, W., Tu, D., & Parulekar, W. R. (2009) · Cancer · doi:10.1002/cncr.24745 · Cited by 90
Billecke, C., Finniss, S., Tahash, L., Miller, C. G., Mikkelsen, T., Farrell, N. P., & Bögler, O. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-004 · Cited by 90
The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin
Servidei, T., Ferlini, C., Riccardi, A., Meco, D., Scambia, G., Segni, G., Manzotti, C., & Riccardi, R. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00061-2 · Cited by 86
Kašpárková, J., Vojtı́šková, M., Natile, G., & Brabec, V. (2007) · Chemistry - A European Journal · doi:10.1002/chem.200701352 · Cited by 84
Stathopoulos, G., Boulikas, T., Vougiouka, M., Rigatos, S., & Stathopoulos, J. (2006) · Oncology Reports · doi:10.3892/or.15.5.1201 · Cited by 82
Lu, C. S., Perez-Soler, R., Piperdi, B., Walsh, G. L., Swisher, S. G., Smythe, W. R., Shin, H. J. C., Ro, J. Y., Feng, L., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.802 · Cited by 79
Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G., Little, M., Yule, S. M., Morland, B. J., Estlin, E., Hale, J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1723 · Cited by 69
Castleberry, R. P., Cantor, A. B., Green, A. A., Joshi, V. P., Berkow, R. L., Buchanan, G. R., Leventhal, B. G., Mahoney, D. H., Smith, E. I., & Hayes, F. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1616 · Cited by 59
Liu, Q., Qu, Y., van Antwerpen, R., & Farrell, N. P. (2006) · Biochemistry · doi:10.1021/bi052517z · Cited by 54
Koukourakis, M. I., Giatromanolaki, A. N., Pitiakoudis, M., Kouklakis, G., Tsoutsou, P. P., Abatzoglou, I. M., Panteliadou, M., Sismanidou, K., Sivridis, E., & Boulikas, T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1733 · Cited by 54
Sharp, S. Y., O'Neill, C., Rogers, P., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00244-7 · Cited by 53
Rosenthal, D. I., Yom, S. S., Liu, L., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1016201732368 · Cited by 51
Shchepinov, M. S. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.18.3864 · Cited by 51
Perez, R. P., O'Dwyer, P. J., Handel, L. M., Ozols, R. F., & Hamilton, T. C. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480219 · Cited by 48
Beale, P. J., Judson, I. R., O’Donnell, A. E., Trigo, J. M., Rees, C., Raynaud, F. I., Turner, A., Simmons, L., & Etterley, L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600854 · Cited by 43
Enzymatic Processing of Platinated RNAs
Chapman, E. G., & DeRose, V. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908419j · Cited by 40
Ravaioli, A., Papi, M., Pasquini, E., Marangolo, M., Rudnas, B., Fantini, M., Nicoletti, S., Drudi, F., Panzini, I., Tamburini, E., et al. (2009) · Journal of Chemotherapy · doi:10.1179/joc.2009.21.1.86 · Cited by 34
Working, P. K., Newman, M. S., Sullivan, T., Brunner, M. P., Podell, M., Sahenk, Z., & Turner, N. (1998) · Toxicological Sciences · doi:10.1006/toxs.1998.2555 · Cited by 32
Kobayashi, H., Takemura, Y., Miyachi, H., & Ogawa, T. (1991) · Investigational New Drugs · doi:10.1007/bf00183571 · Cited by 26
Verschraegen, C. F., Kumagai, S., Davidson, R., Feig, B. W., Mansfield, P. F., Lee, S. J., MacLean, D. S., Hu, W., Khokhar, A. R., & Siddik, Z. H. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0481-3 · Cited by 26
Froudarakis, Μ. E., Pataka, A., Pappas, P., Anevlavis, S., Argiana, E., Nikolaidou, M., Kouliatis, G., Pozova, S., Μαρσέλος, Μ., & Bouros, D. E. (2008) · Cancer · doi:10.1002/cncr.23921 · Cited by 25
Han, I., Ling, Y. H., Al-Baker, S., Khokhar, A. R., & Perez-Soler, R. (1993) · PubMed · Cited by 19
Kurita, H., Yamamoto, E., Nozaki, S., Wada, S., Furuta, I., Miyata, M., & Kurashina, K. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1056-z · Cited by 17
Vokes, E. E., Gordon, G. S., Mauer, A. M., Rudin, C. M., Krauss, S. A., Szeto, L. L., Golomb, H. M., & Hoffman, P. C. (2000) · Clinical Lung Cancer · doi:10.3816/clc.2000.n.025 · Cited by 15
Qu, Y., Tran, M.-C., & Farrell, N. P. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0509-5 · Cited by 14
Karpathiou, G., Argiana, E., Koutsopoulos, A. V., & Froudarakis, Μ. E. (2007) · Oncology · doi:10.1159/000136800 · Cited by 14
Murphy, B. A., Motzer, R. J., & Bosl, G. J. (1992) · Investigational New Drugs · doi:10.1007/bf00944190 · Cited by 13
Cited by
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Metal complexes in cancer therapy – an update from drug design perspective
Ndagi, U., Mhlongo, N., & Soliman, M. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s119488 · Cited by 935
Metadata
- Authors
- Wheate, N. J., Walker, S., Craig, G. E., & Oun, R.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2010
- Volume
- 39
- Issue
- 35
- Pages
- 8113
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2101539565
- Cited by
- 1,634
- References
- 71
- FWCI
- 30.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.